Li, Gang
Toschi, Nicola
Devanarayan, Viswanath
Batrla, Richard
Boccato, Tommaso
Cho, Min
Ferrante, Matteo
Frech, Feride
Galvin, James E.
Henley, David
Mattke, Soeren
De Santi, Susan
Hampel, Harald
Funding for this research was provided by:
Eisai Incorporated
Article History
Received: 19 July 2023
Accepted: 22 November 2023
First Online: 6 December 2023
Declarations
:
: As the study did not constitute human subjects research per US federal regulations (45 CFR 46, 102(f))20, it was exempt from institutional review board (IRB) review, consent requirements, and registration.
: This study involved analyses of MarketScan Commercial and Medicare Databases; thus, no informed consent was feasible or necessary.
: G.L. is an employee of Eisai Inc. N.T. has no declarations of interest. V.D. is an employee of Eisai Inc. R.B. is an employee of Eisai Inc. T.B. has no declarations of interest. M.C. is an employee of Eisai Inc. M.F. has no declarations of interest. F.F. is an employee of Eisai Inc. J.E.G. has provided consultation to Alpha Cognition, Biogen, Cognition Therapeutics, CND Life Sciences, EIP Pharma, Eisai, Eli Lilly, GE Healthcare, Genentech, Otsuka, and Roche. J.G. is the Chief Scientific Officer for Cognivue. J.E.G. is the creator of the Quick Dementia Rating System and holds copyright with the New York University Grossman School of Medicine. J.E.G. is supported by NIA grants R01AG071514, R01AG701514S1, R56AG074889, R01AG071643, R01AG069765, R01AG057681, P01AG066584, and P30AG059295; NINDS grants R01NS101483 and R01NS101483S1. D.H. is an employee of Janssen R&D and a shareholder in Johnson and Johnson. S.M. serves on the board of directors of Senscio Systems, Inc., and the scientific advisory board of AiCure Technologies, Alzpath, and Boston Millennia Partners. S.M. has received consulting and speaker fees from Biogen, C2N, Eisai, Novartis, Novo Nordisk and Roche/Genentech. S.D. is an employee of Eisai Inc. H.H. is an employee of Eisai and serves as reviewing editor for the Journal Alzheimer’s & Dementia. H.H. is inventor of 11 patents and has received no royalties for: In Vitro Multiparameter Determination Method for The Diagnosis and Early Diagnosis of Neurodegenerative Disorders patent no. 8916388; In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases patent no. 8298784; Neurodegenerative Markers for Psychiatric Conditions publication no. 20120196300; In Vitro Multiparameter Determination Method for The Diagnosis and Early Diagnosis of Neurodegenerative Disorders publication no. 20100062463; In Vitro Method for The Diagnosis and Early Diagnosis of Neurodegenerative Disorders publication no. 20100035286; In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases publication no. 20090263822; In Vitro Method for The Diagnosis of Neurodegenerative Diseases patent no. 7547553; CSF Diagnostic in Vitro Method for Diagnosis of Dementias and Neuroinflammatory Diseases publication no. 20080206797; In Vitro Method for The Diagnosis of Neurodegenerative Diseases publication no. 20080199966; Neurodegenerative Markers for Psychiatric Conditions publication no. 20080131921; Method for diagnosis of dementias and neuroinflammatory diseases based on an increased level of procalcitonin in cerebrospinal fluid: US patent no. 10921330.